Anatomy of a Biotech Bipolar Market: Moderna's Costly Surge, Merck's Boom, and the 50% Crash Reality
In the chaotic world of clinical pipelines, the line between euphoric celebration and financial ruin remains razor-thin. What we are witnessing is the perfect culmination of our themes. Here is the Breaking News Analysis: Viral Keyword 'surge': moderna surges after hours on patent settlement with ar...
Read more →